• Osiris Therapeutics Inc., of Columbia, Md., reported that product revenues during the third quarter of 2013 were $6.9 million. Gross profit was $5 million compared to $1.4 million during the same period of 2012. Income from continuing operations was $0.1 million for the third quarter of 2013 compared to a loss from continuing operations of $0.4 million in the same period of the prior year. The company said in connection with the sale of its Prochymal assets, they will recognize a gain of approximately $49 million in the fourth quarter of 2013. On Oct. 10 the assets were sold for $50 million with up to $50 million in potential milestone payments, plus the right to royalties on future sales. The loss from discontinued operations for the nine months ending September 2013 was $8.3 million. Osiris had $35 million in cash at the end of the third quarter.